Acquired drug resistance is a major barrier to curative cancer therapies. I'm excited to share our new study describing a gene therapy platform that proactively targets resistance and enables durable remissions. Out now in @NatureBiotech 🧵below
@varianteffects @WBakhache @CEGS_CMAP Thank you @varianteffects for hosting us! It was a pleasure to speak at the seminar series. It’s always exciting to learn about the cool research showcased in these seminars!
Next up is @ScottLeighow from @JustinPritcha19 lab presenting: Design and construction of evolutionary-guided “selection gene drive” therapy #AACRevol22 Very cool talk!
@doctoralikhan I didn’t lash out. I just don’t share your opinion at all. The very next paragraph in what you have quoted is:
“Palestinian leaders were reportedly taken by surprise. A spokesman for President Mahmoud Abbas said the deal amounted to ‘treason’.”
Our recent paper just got published in PNAS!
The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning https://t.co/at2nCh39ni